Zydus Lifesciences Limited Q1 FY25 consolidated revenue from operations has increased 21% YoY to reach Rs. 6,207.5 crore.

Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues. EBITDA for the quarter was Rs. 2,084 crore, up 38% YoY. EBITDA margin for the quarter stood at 33.6% which is an improvement of 430 bps on a YoY basis. Net profit for the quarter was Rs. 1,419.9 crore up 31% YoY. Capex (organic) for the quarter was Rs. 301.4 crore.

"Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q1 performance. Execution success of our differentiated pipeline in the US and outperformance of our India Geography business were particularly noteworthy. With a focus on quality excellence, we will continue to align our processes and strengthen compliance. We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future," said Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited.